Condition

Heart Failure With Normal Ejection Fraction

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 38 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials38

Recruiting4

Common interventions25

Lead sponsors shown15

Clinical trials

38 shown

Imaging Histone Deacetylase in the HeartNCT03549559 · 2018-09-07

New Orleans Pulmonary Hypertension BiobankNCT03269630 · 2017-12-29

Exercise Intolerance in Heart FailureNCT03775577 · 2017-04-01

Biomechanical Precision Medicine Registry for Patients With and Without Heart FailureNCT03480633 · 2016-04-07

Chronic Exogenous Ketosis in HFpEFNCT06937320 · 2025-07-28

ENROLLING_BY_INVITATION

Ablation Versus Medical Management of Atrial Fibrillation in HFpEFNCT04282850 · 2023-07-10

Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary HypertensionNCT03787082 · 2022-12-01

Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection FractionNCT05477498 · 2021-12-01

High-intensity Interval Training in Heart Failure Patients With Preserved Ejection FractionNCT03184311 · 2020-07-01

Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEFNCT03966755 · 2019-07-23

Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010 · 2019-04-09

Flow Regulation by Opening the Septum in Patients With Heart Failure TrialNCT03751748 · 2019-01-01

Renal Hemodynamics in Patients With HFpEFNCT03672591 · 2018-11-30

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603 · 2018-11-14

β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)NCT03871803 · 2018-10-01

Hemodynamic-GUIDEd Management of Heart FailureNCT03387813 · 2018-03-15

Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection FractionNCT03465072 · 2018-02-01

Validation of CMR Against Invasive Haemodynamics in Patients With HFpEFNCT03251183 · 2018-01-14

Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection FractionNCT03327649 · 2017-12-12

Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection FractionNCT03620526 · 2017-11-29

Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese PatientsNCT03310099 · 2017-10-23

Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)NCT03833336 · 2017-08-23

Heart Function in Patients Assessed for Sleep ApnoeaNCT03226652 · 2017-07-24

Cardiopulmonary Interactions in Patients With Heart FailureNCT03317314 · 2017-07-01

Treatment of HFpEF With Nitrate SupplementNCT03289481 · 2017-06-29

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility StudyNCT03195660 · 2017-06-26

The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.NCT03186833 · 2017-06-06

LYmphangiogenesis FacTors in Heart Failure StatesNCT03141567 · 2017-05-18

Circulating RNAs in Acute Congestive Heart FailureNCT03345446 · 2016-08-17

ACTIVE_NOT_RECRUITING

Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection FractionNCT02744339 · 2016-03-01

Cell Therapy in HFpEFNCT02923609 · 2016-01-01

Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEFNCT02638961 · 2015-10-01

WHISH-2-Prevent Heart FailureNCT03099889 · 2015-04-15

Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection FractionNCT02459626 · 2014-09-01

Interleukin-1 Blockade in HF With Preserved EFNCT02173548 · 2014-09-01

Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise CapacityNCT01919177 · 2013-01-01

Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic FunctionNCT01431027 · 2011-08-01

ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot StudyNCT01347125 · 2008-04-01

Common interventions

Leading sponsors

Massachusetts General Hospital 3 Virginia Commonwealth University 3 Tenax Therapeutics, Inc. 2 Abbott Medical Devices 1 Cantonal Hospital, Baselland 1 CorAssist Cadiovascular Ltd. 1 Corporal Michael J. Crescenz VA Medical Center 1 Duke University 1 Fundación para la Investigación del Hospital Clínico de Valencia 1 Gladwin, Mark, MD 1 Goethe University 1 Hannover Medical School 1 Heart Center Leipzig - University Hospital 1 Imperial College London 1 Inova Health Care Services 1

Trial status mix

COMPLETED21

RECRUITING4

UNKNOWN4

TERMINATED3

WITHDRAWN3

ACTIVE_NOT_RECRUITING1

ENROLLING_BY_INVITATION1

SUSPENDED1

Phase mix

NA12

PHASE27

PHASE43

EARLY_PHASE12

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.